In this SOHO Insider interview from the AACR Annual Meeting 2026, Ramesh Balusu, PhD, scientific director of the Midwest Stem Cell Therapy Center and assistant professor at the University of Kansas Medical Center, discusses the results of point-of-care tri-specific (CD19/20/22) CAR T-cell therapy from a phase 1 trial.
The investigator-initiated trial evaluated DuoCAR20.19.22-D95 in adults with relapsed or refractory B-cell malignancies who have often failed prior CAR T-cell treatments. The heavily pretreated patient population had a median age of approximately 40 years old.
Dr. Balusu said that they hope to recruit a larger cohort of patients and expand the trial to other cancers centers. The trial is currently in the dose-escalation phase.
The title of this abstract is “Point-of-care manufacturing and early clinical evaluation of a tri-specific (CD19/20/22) CAR T-cell therapy for relapsed or refractory (R/R) B-cell malignancies.” Abstract# CT269.
Leave feedback about this